These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 17099725)

  • 1. Ink4c is dispensable for tumor suppression in Myc-induced B-cell lymphomagenesis.
    Nilsson LM; Keller UB; Yang C; Nilsson JA; Cleveland JL; Roussel MF
    Oncogene; 2007 May; 26(20):2833-9. PubMed ID: 17099725
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nfkb 1 is dispensable for Myc-induced lymphomagenesis.
    Keller U; Nilsson JA; Maclean KH; Old JB; Cleveland JL
    Oncogene; 2005 Sep; 24(41):6231-40. PubMed ID: 15940251
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting ornithine decarboxylase in Myc-induced lymphomagenesis prevents tumor formation.
    Nilsson JA; Keller UB; Baudino TA; Yang C; Norton S; Old JA; Nilsson LM; Neale G; Kramer DL; Porter CW; Cleveland JL
    Cancer Cell; 2005 May; 7(5):433-44. PubMed ID: 15894264
    [TBL] [Abstract][Full Text] [Related]  

  • 4. AID and RAG1 do not contribute to lymphomagenesis in Emu c-myc transgenic mice.
    Nepal RM; Zaheen A; Basit W; Li L; Berger SA; Martin A
    Oncogene; 2008 Aug; 27(34):4752-6. PubMed ID: 18408759
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MIF loss impairs Myc-induced lymphomagenesis.
    Talos F; Mena P; Fingerle-Rowson G; Moll U; Petrenko O
    Cell Death Differ; 2005 Oct; 12(10):1319-28. PubMed ID: 15947793
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Id2 is dispensable for myc-induced lymphomagenesis.
    Nilsson JA; Nilsson LM; Keller U; Yokota Y; Boyd K; Cleveland JL
    Cancer Res; 2004 Oct; 64(20):7296-301. PubMed ID: 15492249
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A non-transgenic mouse model for B-cell lymphoma: in vivo infection of p53-null bone marrow progenitors by a Myc retrovirus is sufficient for tumorigenesis.
    Yu D; Thomas-Tikhonenko A
    Oncogene; 2002 Mar; 21(12):1922-7. PubMed ID: 11896625
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transgenic N-myc mouse model for indolent B cell lymphoma: tumor characterization and analysis of genetic alterations in spontaneous and retrovirally accelerated tumors.
    Sheppard RD; Samant SA; Rosenberg M; Silver LM; Cole MD
    Oncogene; 1998 Oct; 17(16):2073-85. PubMed ID: 9798678
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Insertion of c-Myc into Igh induces B-cell and plasma-cell neoplasms in mice.
    Park SS; Kim JS; Tessarollo L; Owens JD; Peng L; Han SS; Tae Chung S; Torrey TA; Cheung WC; Polakiewicz RD; McNeil N; Ried T; Mushinski JF; Morse HC; Janz S
    Cancer Res; 2005 Feb; 65(4):1306-15. PubMed ID: 15735016
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Loss of Fas/Apo-1 receptor accelerates lymphomagenesis in E mu L-MYC transgenic mice but not in animals infected with MoMuLV.
    Zörnig M; Grzeschiczek A; Kowalski MB; Hartmann KU; Möröy T
    Oncogene; 1995 Jun; 10(12):2397-401. PubMed ID: 7784089
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synergistic effect of oncogenic RET and loss of p18 on medullary thyroid carcinoma development.
    van Veelen W; van Gasteren CJ; Acton DS; Franklin DS; Berger R; Lips CJ; Höppener JW
    Cancer Res; 2008 Mar; 68(5):1329-37. PubMed ID: 18316595
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The functional basis of c-myc and bcl-2 complementation during multistep lymphomagenesis in vivo.
    Marin MC; Hsu B; Stephens LC; Brisbay S; McDonnell TJ
    Exp Cell Res; 1995 Apr; 217(2):240-7. PubMed ID: 7698223
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Runx2 and MYC collaborate in lymphoma development by suppressing apoptotic and growth arrest pathways in vivo.
    Blyth K; Vaillant F; Hanlon L; Mackay N; Bell M; Jenkins A; Neil JC; Cameron ER
    Cancer Res; 2006 Feb; 66(4):2195-201. PubMed ID: 16489021
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A murine model for B-cell lymphomagenesis in immunocompromised hosts: c-myc-rearranged B-cell lines with a premalignant phenotype.
    Felsher DW; Denis KA; Weiss D; Ando DT; Braun J
    Cancer Res; 1990 Nov; 50(21):7042-9. PubMed ID: 2208171
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Loss of one allele of ARF rescues Mdm2 haploinsufficiency effects on apoptosis and lymphoma development.
    Eischen CM; Alt JR; Wang P
    Oncogene; 2004 Nov; 23(55):8931-40. PubMed ID: 15467748
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Myc targets Cks1 to provoke the suppression of p27Kip1, proliferation and lymphomagenesis.
    Keller UB; Old JB; Dorsey FC; Nilsson JA; Nilsson L; MacLean KH; Chung L; Yang C; Spruck C; Boyd K; Reed SI; Cleveland JL
    EMBO J; 2007 May; 26(10):2562-74. PubMed ID: 17464290
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Disruption of the ARF-Mdm2-p53 tumor suppressor pathway in Myc-induced lymphomagenesis.
    Eischen CM; Weber JD; Roussel MF; Sherr CJ; Cleveland JL
    Genes Dev; 1999 Oct; 13(20):2658-69. PubMed ID: 10541552
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of p16Ink4a compensates for p18Ink4c loss in cyclin-dependent kinase 4/6-dependent tumors and tissues.
    Ramsey MR; Krishnamurthy J; Pei XH; Torrice C; Lin W; Carrasco DR; Ligon KL; Xiong Y; Sharpless NE
    Cancer Res; 2007 May; 67(10):4732-41. PubMed ID: 17510401
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The translation factor eIF-4E promotes tumor formation and cooperates with c-Myc in lymphomagenesis.
    Ruggero D; Montanaro L; Ma L; Xu W; Londei P; Cordon-Cardo C; Pandolfi PP
    Nat Med; 2004 May; 10(5):484-6. PubMed ID: 15098029
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chemoprevention of B-cell lymphomas by inhibition of the Myc target spermidine synthase.
    Forshell TP; Rimpi S; Nilsson JA
    Cancer Prev Res (Phila); 2010 Feb; 3(2):140-7. PubMed ID: 20103729
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.